key: cord-0853535-w68ljpfa
authors: Barach, Paul; Lipshultz, Steven E.
title: Rethinking COVID-19 in children: Lessons learned from pediatric viral and inflammatory cardiovascular diseases
date: 2020-05-22
journal: Prog Pediatr Cardiol
DOI: 10.1016/j.ppedcard.2020.101233
sha: 1eb880029ffe02061a1a83e477a4b128757ef293
doc_id: 853535
cord_uid: w68ljpfa

nan

J o u r n a l P r e -p r o o f 5 respiratory symptoms, and 18 (38%) required invasive ventilation. Hospital mortality was 4.2%

(2 of 48) [22] .

In a March 2020 study of households with confirmed COVID-19 cases in Shenzhen, China, [23] children younger than 10 years were just as likely as adults to become infected but were much less likely to have severe symptoms. However, other media reports, including some from South Korea, Italy, and Iceland, where testing has been more widespread, mentioned lower infection rates among children than among adults. Some Chinese studies also support the possibility that children are less susceptible to infection. One analyzed data from contact tracing in the Province of Hunan, China [24] . For every infected child under the age of 15 years, almost 3 adults between the ages of 20 and 64 were infected (odds ratio, 0.34; 95% CI, 0.24 to 0.49). A preliminary analysis of 300 infected children found that they produced much lower concentrations of cytokines than did infected adults. Cytokines are proteins released by the immune system; a fact consistent with Kawasaki disease as a condition associated with acquired immune dysfunction. Cytokines depress heart function through direct immune activation which can be associated with myocytolysis.

Increasing evidence suggests that bodily tissue damage in COVID-19 is mostly mediated by the host's innate immunity [25, 26] . The disease is characterized by a cytokine storm J o u r n a l P r e -p r o o f

Clinical myocarditis is uncommon in infants and children, but most cases in children are caused by a viral infection. J o u r n a l P r e -p r o o f 9 However, from longitudinal follow-ups of other virus-exposed or infected children, we have learned that viral-associated cardiovascular diseases in children are much more complicated than indicated by the mere assessment of systolic ventricular performance [67] . Assessing the global risk of developing symptomatic cardiovascular disease by using Pathobiological Determinants of Atherosclerosis in Youth coronary arteries and abdominal aorta risk scores calculated by measuring a combination of modifiable risk factors, along with other surrogate markers of symptomatic cardiovascular disease, are more informative than assessing systolic ventricular performance alone [67] . For example, although antiviral therapy increases LV systolic performance in virus-exposed or infected children, it can also result in long-term diastolic dysfunction [68] , as well as other major persistent or progressive cardiovascular issues.

One of the remarkable outcomes is that these hearts often remain too small for the body as these children grow, perhaps because of the stunting effects of viral replication leading to stunting of cardiac growth [69, 70] , which may eventually be associated with premature symptomatic cardiovascular diseases.

Children with myocarditis who have a swollen endothelium and depressed heart function are particularly vulnerable to cardiotoxic medications, such as hydroxychloroquine alone or in combination with azithromycin [71] . This vulnerability is secondary to genetic susceptibility and variability and is associated with mitochondria mutations [72] . Antiviral therapy-associated cardiotoxicity in these children is not a class effect. Rather, specific antiviral therapies can have more deleterious effects on cardiovascular structure and function [73] , allowing antiviral therapy to be tailored to achieve the greatest efficacy while minimizing cardiovascular toxicity. Several over-the-counter medications have been removed from the market, because they can increase the risk of QT-prolongation, which is associated with sudden death in children with myocarditis and Journal Pre-proof J o u r n a l P r e -p r o o f 10 other heart damage [74] . For example, the US FDA issued a -Black Box‖ warning that longacting stimulant therapy for children with underlying cardiovascular disease should be carefully assessed, given a possible association with sudden death [75, 76] .

Multicenter, pediatric cardiovascular disease registries comprised of prospectively collected data have supported treatments that have reduced the failure of medical management of cardiomyopathy by 50% at participating centers [77] , emphasizing the importance of registrybased research that may lend itself to COVID-19 cardiovascular diseases. With data from a registry, we recently developed a new classification system for pediatric myocardial diseases [78] by identifying differences in the course and outcomes specific to the causes of several cardiomyopathies [79] . Competing-risk analyses established that children with suspected myocarditis have outcomes similar to those in children with histologically proven myocarditis, a finding that can avoid the risks of biopsy. Although echocardiograms of children with myocarditis may be similar to those with dilated cardiomyopathy, their course and outcomes differ, which may help manage COVID-10 cardiac disease [54].

A final note here about the how to ensure the safety of the providers caring for children with COVID-19. In the current climate with the COVID-19 pandemic there is significant concern amongst all clinicians around the potential consequences of being infected, including history of immune suppression, diabetes, heart disease, and also seems to have an increased effect in the Black, Asian and Minority Ethnic (BAME) community due to the excess deaths faced by this cohort [80, 81] . Several groups around the world are recommending to risk stratify healthcare workers as a way to best protect healthcare workers that are most at risk of getting J o u r n a l P r e -p r o o f 11 infected [82] . Related, the coronavirus pandemic has greatly affected how echocardiograms are acquired in the intensive care unit and perioperative settings. Careful consideration of the indications, venues, and approaches for echocardiographic imaging will protect healthcare providers, and preserve the operational integrity of health systems [83] . Echocardiography personnel can be further protected by carefully reassigning those at increased risk for infection, such as advanced age, chronic conditions, immunosuppression, and pregnancy [84] .

COVID-19-associated cardiovascular disease is thought to be associated with both immune activation and viral effects in some affected children. This immune vulnerability makes it imperative to determine whether this Kawasaki disease-like illness is causally associated with COVID-19 and, if so, to identify the biological and immunological processes involved. Tomisaku Kawasaki first reported his 50 cases in Japan a half-century ago, but the definitive causes of Kawasaki disease remain unknown [31] . Serum cardiac troponin concentrations are consistent with active cardiomyocyte injury that goes beyond the oftenreversible myocardial depressant effects of certain cytokines that are activated or that -storm‖ in some of these children. These conditions suggest that children are likely to experience long-term cardiovascular effects because cardiomyocyte death or mitochondrial damage are often irreversible.

J o u r n a l P r e -p r o o f 13 differ between children who have asthma or other allergic conditions and children who do not [97] .

For children with presumed acute-onset viral disease, detecting active myocardial involvement is critical because its symptoms can be wrongly attributed to respiratory or infectious complications, delaying appropriate therapy [98, 99] . We found that nearly 10% of children presenting to the emergency department of a major children's hospital with presumptive viral febrile illnesses had active myocardial injury, characterized with dead and dying cardiomyocytes, and about 2% had serum concentrations of cardiac troponin T similar to those found in adults with acute myocardial infarctions. Yet for these young children, cardiac involvement was clinically unsuspected [100] . -If you don't look for it, you may not find it.‖ Further, some of these cardiac biomarkers are validated predictors of long-term cardiovascular health or disease in children, which better informs treatment decisions in high-risk groups [101] .

The possibility of unsuspected myocardial injury suggests that children with symptoms of COVID-19 infection should also be screened for cardiac involvement by measuring serum concentrations of cardiac troponin and NT-proBNP, both of which have low costs in time and money and would not delay potentially more appropriate therapy.

We believe the growing threat to children from COVID-19 supports the following recommendations for policymakers and clinicians. Assuring adequate availability of personal protective equipment is just the first step; other measures must be considered, including cancelling of non-essential medical care and group events to concentrate resources and providing food, rest, and personal and family psychological support [120] . In any pandemic, health-care workers are every country's most valuable resource.

Care is the Future. The movement toward virtual visits aims to protect children, their families, and healthcare workers from exposure to COVID-19, so eliminating as much in-person traffic and contact as possible at hospital and clinics is essential. Telemedicine is not new, but the urgency of the COVID-19 crisis has forced most healthcare organizations to make radical shifts to telehealth within a few weeks, transitioning most appointments to a telemedicine platform. Using appropriately software, clinicians can carefully triage upcoming appointments to select children most appropriate for telemedicine visits and those who should be seen in person, such as patients who need to come in for chemotherapy infusions. We need to better understand how and when to best use patient-facing digital Journal Pre-proof health technologies and how these technologies influence the quality, safety, and satisfaction of children and their families [121] .

6. Inequity. Pediatricians, health service researchers, and policy makers are not at all surprised to read headlines about the disproportionately high numbers of COVID-19 deaths among the poor, underrepresented minorities (black and minority ethnic backgrounds) and people who are in nursing homes, marginalized and homeless, incarcerated, highly religious, and indigenous. Unfortunately, the number of minority healthcare providers and social workers that have been infected and died is also disproportionally high [81] . It is time to commit the resources and political will to address inequalities in care, especially among children. 

A novel coronavirus from patients with pneumonia in China

World Health Organization. Q&A on coronaviruses (COVID-19)

Lessons unfolding from pediatric cases of COVID-19 disease caused by SARS-CoV-2 infection

A pediatric emergency department protocol to avoid intra-hospital dispersal of SARS-CoV-2 during the outbreak in Bergamo, Italy

Epidemiology of COVID-19 among children in China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children: A systematic review

Abnormalities of cardiac structure and function in HIV-infected children treated with zidovudine

Cardiac morbidity and related mortality in children with symptomatic HIV infection

Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome

for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Cardiac structure and function in children infected with human immunodeficiency virus. The prospective P 2 C 2 HIV and mortality in HIV-infected children. The prospective P 2 C 2 HIV multicenter study

Absence of cardiac toxicity of zidovudine in infants

The P 2 C 2 HIV Study Group. Cardiovascular status of infants and children of women infected with HIV-1 (P 2 C 2 HIV): a cohort study

Hyperinflammatory shock in children during COVID-19 pandemic

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C)

Early differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a pediatric intensive care unit

A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan

Coronavirus causes damaging blood clots from brain to toes

is 1 st French death from likely COVID-linked illness

Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study

Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study)

Declining incidence of systolic left ventricular dysfunction in Human Immunodeficiency Virus-infected individuals treated with highly active antiretroviral therapy

Immunoglobulins and cardiac structure and function in HIV-infected children

Cardiac and inflammatory biomarkers in

Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1

Aggregate risk of cardiovascular disease among adolescents perinatally infected with the Human Immunodeficiency Virus

Left ventricular diastolic dysfunction in HIVuninfected infants exposed in utero to antiretroviral therapy

Cardiac effects of highly active antiretroviral therapy in perinatally HIV-infected children: The CHAART-2 study

Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers

NIH panel recommends against drug combination promoted by Trump for COVID-19. National Public Radio

Drug-induced mitochondrial dysfunction and cardiotoxicity

Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies

Drug-induced QT interval prolongation: mechanisms and clinical management

Health effects of energy drinks on children, adolescents, and young adults

Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence

Survival without cardiac transplantation among children with dilated cardiomyopathy

Cardiomyopathy in children: classification and diagnosis: A scientific statement from the American Heart Association

Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group

Risk stratification for healthcare workers during

CoViD-19 pandemic: using demographics, co-morbid disease and clinical domain in order to assign clinical duties. Medrxiv (the preprint server for health sciences)

Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities

Risk reduction framework for NHS staff at risk of COVID-19 infection

Preventing infection of patients and healthcare workers should be the new normal in the era of novel coronavirus epidemics

Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. Letter to the Editor

Drug-induced mitochondrial cardiomyopathy and cardiovascular risks in children

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term followup of a prospective, randomised, multicentre trial

Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors

Ventricular dysfunction clinical research in infants, children and adolescents

Realizing optimal care for children with cardiovascular disease: Funding challenges and research approaches

Clinical research directions in pediatric cardiology

Study to determine incidence of novel coronavirus infection in U.S. children begins. NIH-funded study also will ascertain percentage of infected children who develop COVID-19

Pediatric and Congenital Cardiac Care

Pediatric and Congenital Cardiac Care

Frequency of clinically unsuspected myocardial injury at a children's hospital

Changes in cardiac biomarkers during doxorubicin treatment of children with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes

Thinking in Systems: A Primer

Improvement in interstage survival in a national pediatric cardiology learning network. National Pediatric Cardiology Quality Improvement Collaborative

Towards a learning system for pediatric cardiomyopathy: harvesting meaning from evidence

Towards a Learning System for Enhanced Recovery After Surgery (ERAS): Embedding Implementation and Learning Evaluatio

Crisis checklists for in-hospital emergencies: expert consensus, simulation testing and recommendations for a template determined by a multiinstitutional and multidisciplinary learning collaborative

Diffusion of innovations in service organizations: systematic review and recommendations

What is operative morbidity? Defining complications in a surgical registry database: a report of the STS Congenital Database Taskforce and the Joint EACTS-STS Congenital Database Committee

Pulmonary complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease

Evaluating policy and service interventions: framework to guide selection and interpretation of study end points

Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: results from the Pediatric Cardiomyopathy Registry

Incidence, causes and outcomes of dilated cardiomyopathy in children

The benefits and hazards of publicly reported quality outcomes

Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry

Readmitting children with heart failure: the importance of communication, coordination, and continuity of care

Does lowering heart rate improve outcomes in children with dilated cardiomyopathy and chronic heart failure?

What hospitals and health care workers need to fight coronavirus

Exclusive: deaths of NHS staff from covid-19 analysed. HSJ for Healthcare Leaders

The Lancet. COVID-19: protecting health-care workers (Editorial)

Annals On Call -Protecting health care workers from COVID-19

Assessing the impact of patient-facing digital technology on patient outcomes: a retrospective observational cohort study. JMIR mHealth and uHealth